ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IGX Intelgenx Technologies Corp

0.58
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Intelgenx Technologies Corp TSXV:IGX TSX Venture Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.58 0.54 0.65 0 01:00:00

IntelGenx Engages Focus Communications for Investor Relations Program

30/11/2018 1:00pm

GlobeNewswire Inc.


Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Intelgenx Technologies Charts.

IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce the engagement of Focus Communications (“Focus”) to provide online marketing and corporate communications services to the Company.  Focus has been retained on a twelve month contract basis to advise the Company with respect to its online marketing endeavours and assisting management in developing a strategy to help expand and support corporate development initiatives. Focus will also assist IntelGenx in increasing investor awareness by managing the Company’s corporate communications, marketing undertakings, ongoing engagement with shareholders, finance professionals and media contacts.

Under the terms of the agreement, IntelGenx will pay Focus Communications C$5,000 per month for an initial twelve month term and grant 100,000 stock options at an exercise price of US$0.81.

About Focus Communications

Focus Communications is a private Toronto based firm providing investor relations, corporate communications and market awareness services. Focus implements a proactive and “one on one” approach in managing relationships between clients, their shareholders and the investment community while specializing in executing strategic marketing initiatives that enhance liquidity and create greater visibility within the capital markets.

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information is available about the Company at: www.intelgenx.com.

Forward-Looking Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:

Stephen Kilmer
Investor Relations 
(514) 331-7440 ext 232
stephen@intelgenx.com

Or

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

1 Year Intelgenx Technologies Chart

1 Year Intelgenx Technologies Chart

1 Month Intelgenx Technologies Chart

1 Month Intelgenx Technologies Chart

Your Recent History

Delayed Upgrade Clock